Latest Us Capital Markets News

US1 Critical Minerals reports ongoing legal disputes over US rare earth tenements while advancing Tanzanian uranium exploration and securing $1.5 million in new capital.

Locksley Resources has made significant strides at its Mojave Project, advancing drilling, securing major US institutional funding, and forging key partnerships to establish a domestic supply chain for critical antimony and rare earth elements.

Neurizon Therapeutics has cleared a major regulatory hurdle with the FDA lifting the clinical hold on its lead drug NUZ-001 and secured a comprehensive $33 million funding package to advance its pivotal ALS trial.

Brookside Energy delivered steady production and strong cash flow from its Anadarko Basin assets in the December 2025 quarter, while advancing its Riverbend project and continuing an active share buy-back program.

Metallium Limited has kicked off commissioning at its Texas Technology Campus, sealed a multi-year feedstock deal with Glencore, and bolstered its balance sheet with a A$75 million capital raise, setting the stage for commercialisation in 2026.

Energy Transition Minerals Ltd (ETM) reported key progress in its December 2025 quarter, including legal developments for its Greenland rare earth project, advancing a strategic mine acquisition in Spain, and moves toward a US Nasdaq listing.

Jindalee Lithium has secured US government approval for its McDermitt Lithium Project’s exploration plan, reported strong drilling results, and extended exclusivity on a US SPAC listing valued at US$500 million.

American Tungsten & Antimony Ltd is progressing its Nasdaq listing plans with a confidential SEC filing expected in March 2026 and has appointed Deutsche Bank as ADR depositary alongside a new CFO to support growth.

Energy Transition Minerals (ETM) has appointed Ballard Partners as strategic advisors in the US, reinforcing its plan to list on the Nasdaq Stock Exchange and deepen its engagement with American stakeholders.

Red Mountain Mining Ltd has made a strong entrance on the US OTCQB market, surging 36% on its first day of trading as it advances key antimony and gold projects across the US and Australia.

Argent BioPharma has locked in an A$11 million convertible financing facility to finalize its strategic acquisition of AusCann assets and accelerate its growth plans, including a potential US stock exchange listing.

Alliance Nickel has confirmed the technical strength of its NiWest project while navigating market headwinds and Stellantis’ offtake renegotiation, as it pursues a Nasdaq listing via SPAC to tap US capital markets.